SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of...
Related Questions
How will the debt refinancing affect QuidelOrtho's capital structure and future earnings guidance?
What are the specific terms of the refinancing (interest rate, maturity, covenants) and how do they compare to market benchmarks?
Could the refinancing change the company's credit rating or financing flexibility relative to its peers in the diagnostics sector?